Cancer drug developer CG Oncology valued at $1.75 bln in strong …

Jan 25, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up …

CouponFollow Extension

6%
OFF

Cancer Drug Developer CG Oncology Valued At $1.75 Bln In Strong …

21 hours ago

Jan 25, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up …

reuters.com

6%
OFF

UPDATE 2-Cancer Drug Developer CG Oncology Valued At $1.75 …

21 hours ago

Jan 25, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up …

yahoo.com

6%
OFF

CG Oncology Valued At $1.75 Bln In Strong Market Debut - Nasdaq

21 hours ago

Jan 25, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as demand for new …

nasdaq.com

6%
OFF

CG Oncology Valued At $1.75 Bln In Strong Market Debut - Yahoo …

21 hours ago

CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after shares of the cancer drug developer rose 52.6% at the open on the Nasdaq.

yahoo.com

$1.75
OFF

CG Oncology, Inc. (CGON) Stock Price, Quote & News - Stock …

21 hours ago

5 days ago · CG Oncology valued at $1.75 bln in strong market debut. CG Oncology CGON.O notched up a valuation of $1.75 billion in its market debut on Thursday, after shares of the …

stockanalysis.com

6%
OFF

Cancer Drug Developer CG Oncology Valued At $1.75 Billion In …

21 hours ago

Jan 25, 2024 · (Reuters) -Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new …

yahoo.com

6%
OFF

CG Oncology Inc | Reuters

21 hours ago

Feb 9, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up …

reuters.com

6%
OFF

CG Oncology Valued At $1.75 Bln In Strong Market Debut

21 hours ago

Jan 25, 2024 · CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after shares of the cancer drug developer rose 52.6% at the open on the Nasdaq. ...

marketscreener.com

96%
OFF

CG Oncology IPO Rockets 96% In Sign Of Pent-up Deal Demand

21 hours ago

Jan 25, 2024 · Irving, Calif.-based CG Oncology's stock (CGON) closed its first day of trading at $37.17 a share, up 95.6% from its $19 IPO price and well above its opening trade of $29 a share.

morningstar.com

$2.31
OFF

CG Oncology (CGON) Market Cap & Net Worth - Stock Analysis

21 hours ago

3 days ago · CG Oncology has a market cap or net worth of $2.31 billion as of November 27, 2024. ... Market Cap 2.31B. Enterprise Value 1.77B. 1-Year Change n/a. Ranking # 1907. …

stockanalysis.com

$1
OFF

UPDATE 1-CG Oncology Targets Near $1 Bln Valuation In US IPO

21 hours ago

Jan 18, 2024 · (Adds details on company's business, IPO terms in paragraphs 2-6) Jan 18 (Reuters) - Cancer drug developer CG Oncology said on Thursday it was targeting a valuation …

yahoo.com

$1
OFF

CG Oncology Targets Near $1 Bln Valuation In US IPO | Reuters

21 hours ago

Jan 18 (Reuters) - Cancer drug developer CG Oncology said on Thursday it was targeting a valuation of nearly $1 billion for its initial public offering. The company is developing a therapy …

reuters.com

FAQs about Cancer drug developer CG Oncology valued at $1.75 bln in strong … Coupon?

How much is CG oncology worth?

Jan 25 (Reuters) - Cancer drug developer CG Oncology (CGON.O) notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up pace. ...

How did CG oncology raise $380 million?

The firm sold 20 million shares in its offering and raised $380 million. CG Oncology's initial public offering (IPO), the first by a biotech firm this year, sets the stage for other healthcare companies such as KKR-backed BrightSpring Health Services and Moderna-backed Metagenomi. ...

Is CG oncology a good IPO?

Biotech stocks have fallen about 1% so far this year. With a lead asset in advanced Phase-III testing, CG Oncology, which debuts Thursday on the NASDAQ, is one of the year's most highly anticipated IPOs. The company's lead drug targets a sizable addressa... ...

Who are CG oncology's biggest shareholders?

Biotech investor ORI Capital and life sciences investor Decheng Capital are its biggest shareholders. CG Oncology is one of a handful of companies from the healthcare sector looking to list in the coming months, as a market rally on hopes of a soft landing for the economy eases pressure on startups looking to go public. ...

Will CG Oncology GO Public?

The firm aims to list on the Nasdaq under the symbol CGON. CG Oncology has filed to go public with an IPO on the NASDAQ. CG Oncology has received fast track designation and breakthrough designation needed to accelerate US FDA submission. ...

What does CG oncology stand for?

IRVINE, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone blad... ...